Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 9/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 5/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554526 | 0.85 | NAMPT (0.43) | ACACBCTSAPIN1 | |
| SCHEMBL7560667 | 0.85 | F10 (0.41) | ACACBCTSA | |
| Hydrochloric Acid SCHEMBL7558907 | 0.84 | F10 (0.41) | ACACBCTSA | |
| SCHEMBL6340535 | 0.77 | SLC6A9 (0.44) | ACACB | |
| SCHEMBL7566304 | 0.77 | ACACB (0.41) | ACACBFASN | |
| SCHEMBL6342009 | 0.76 | NAMPT (0.43) | CTSAEGLN1EGLN2PIN1 | |
| SCHEMBL6554528 | 0.76 | NAMPT (0.43) | ACACB | |
| SCHEMBL6554476 | 0.75 | SLC6A9 (0.45) | ACACB | |
| SCHEMBL6556808 | 0.74 | ACACB (0.53) | ACACBFASN | |
| Hydrochloric Acid SCHEMBL6556783 | 0.74 | ITGB3 (0.41) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | ACACB 2861/4885CTSA 2783/4885EGLN1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.